About the Journal

Journal of Translational Medicine & Biopharmaceuticals (JTMB) is an open-access, peer-reviewed journal publishing high-quality research at the interface of basic discovery, clinical development, and biopharmaceutical innovation. The journal provides a multidisciplinary platform for scientists, clinicians, and industry professionals to share findings that accelerate the translation of laboratory insights into safe and effective therapies.

JTMB aims to integrate fundamental and applied research across preclinical models, clinical investigation, pharmaceutical sciences, and regulatory science. By fostering collaboration and rigorous knowledge dissemination, the journal contributes to innovations in drug, biologic, cell/gene therapy development, diagnostics, and precision medicine.

The journal welcomes original research, reviews, and case studies focusing on current developments and interdisciplinary applications in translational medicine and biopharmaceutical R&D. Areas of interest include (but are not limited to):

• Target discovery, biomarkers, and companion diagnostics
• Preclinical pharmacology, toxicology, and IND-enabling studies
• Clinical trial design, Phase I–IV studies, and real-world evidence
• Biologics, vaccines, and advanced therapies (cell & gene, RNA)
• Pharmaceutics, CMC, and bioprocess development
• Pharmacokinetics/PD, modeling & simulation, and dose optimization
• Regulatory science, quality by design, and compliance
• Drug delivery systems, nanomedicine, and translational imaging
• Health economics, access, and patient-reported outcomes
• Digital health, AI/ML in drug development, and trial operations

JTMB is published under an open-access model, ensuring unrestricted access to all published content for researchers and readers worldwide.

The journal operates under the Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing users to read, distribute, and reproduce material in any medium, provided the original work is properly cited.

View CC BY 4.0 License

All submissions undergo a rigorous double-blind peer-review process to ensure scientific validity, originality, and research integrity.

The editorial board comprises experts from translational science, clinical research, pharmaceutical sciences, and regulatory affairs, committed to maintaining ethical and professional standards in scholarly publishing.

• Original Research Articles
• Review and Systematic Studies
• Theoretical and Conceptual Papers
• Case Reports and Technical Notes (including protocols)
• Short Communications and Commentary Articles